Inovio Pharmaceuticals, Inc. (INO)

12.01 +0.33 (+2.83%) At close: 4:00PM EST

Inovio Pharmaceuticals, Inc.

660 West Germantown Pike
Suite 110
Plymouth Meeting, PA 19462
United States
267 440 4200
http://www.inovio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 190

Key executives

Name	Title	Pay	Exercised	Year born
Dr. J. Joseph Kim	CEO, Pres & Director	1.31M	N/A	1969
Mr. Peter D. Kies	Chief Financial Officer	711.13k	N/A	1963
Dr. Jacqueline E. Shea Ph.D.	Chief Operating Officer	611.75k	N/A	1966
Dr. Laurent M. Humeau	Chief Scientific Officer	572.16k	N/A	1967
Ben Matone	Director of Investor Relations	N/A	N/A	N/A
Mr. Jeffrey C. Richardson	VP of Communications & Strategic Relations	N/A	N/A	N/A
Mr. E. J. Brandreth	Sr. VP of Quality Assurance	N/A	N/A	N/A
Ms. Jessica C. Lee MS, MPH	Sr. VP of Clinical Operations & Global Integration	N/A	N/A	N/A
Dr. Prakash Bhuyan	Sr. VP of Clinical Devel.	N/A	N/A	N/A
Dr. Ami Shah Brown	Sr. VP of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Corporate governance

Inovio Pharmaceuticals, Inc.’s ISS governance QualityScore as of 2 December 2020 is 3. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.